HBSP (USA)
-
Amgen Inc.: Pursuing Innovation and Imitation? (A)
Mackenzie, Ian WCase HBS-714424-EStrategySet in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification: innovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed growth. But the possibility sparked a strong negative reaction within Amgen, not least bec...Starting at €8.20
-
Uber and the Taxi Industry (A)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715433-EStrategyStarting at €8.20
-
UberX & Lyft (B)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715434-EStrategySupplement case for 715433.Starting at €5.74
-
Optimization and Expansion at OpenTable
Edelman, Benjamin; Webster, Karen L.Case HBS-915003-EStrategyOpenTable considers adjustments to increase its benefits to merchants, including a novel payments service that lets customers skip the multi-step process of using a credit card.Starting at €8.20
-
Pursuing Innovation and Imitation? (A) (Spanish version)
Mackenzie, Ian WCase HBS-719S12Strategyinnovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed growth. But the possibility sparked a strong negative reaction within Amgen, not least because it contravened Amgen's mission. Internal debate was exacerbated by the presence of considerable uncertainty over the regulatory requirements for BS development and how difficult it would be to develop a BS. Some felt it played to Amgen's strengths, others fel...Starting at €8.20
-
Amgen Inc.: Pursuing Innovation and Imitation (B)
Mackenzie, Ian WCase HBS-714426-EStrategyThe (B) case reveals that Sharer decided that Amgen should the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The (B) case then focuses on how the new business should be implemented, particularly in terms of integration versus separation of a new business unit, choice of unit leader, and whether Amgen ...Starting at €5.74
-
Reinventing Retail: ShopRunner's Network Bet (Spanish Version)
Edelman, Benjamin; Webster, Karen L.Case HBS-918S06MarketingShopRunner considera ajustes para mejorar su servicio de compras en línea que ofrece servicios sin cargo de envío de dos días, así como devoluciones fáciles y otras comodidades. diversos modelos de precios de los competidores y beneficios secundarios plantean preguntas acerca de cómo estructurar y oferta de precio de ShopRunner. Mientras tanto, una inversión de Alibaba presenta nuevas oportunidades en China, pero corre el riesgo de distracción de...Starting at €8.20
-
Optimization and Expansion at OpenTable (Spanish Version)
Edelman, Benjamin; Webster, Karen L.Case HBS-918S17StrategyIntervalo considera ajustes para aumentar sus beneficios a los comerciantes, incluyendo un servicio de nuevos pagos que permite a los clientes omitir el proceso de múltiples pasos de utilizar una tarjeta de crédito.Starting at €8.20
-
Uber y la industria del Taxi (A)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-716S07StrategyStarting at €8.20
-
Amgen Inc: Pursuing Innovation and Imitation (A), (B)
Mackenzie, Ian WTeaching Note HBS-714425-EStrategyTeaching Note for 714424 and 714426.Starting at €0.00